OncoDaily Academy Is Now Live: Free Global Oncology Education Starts Today

OncoDaily Academy Is Now Live: Free Global Oncology Education Starts Today

OncoDaily Academy officially launches today, November 16, 2026, opening a new global platform for accessible, clinically relevant and expert-led oncology education.

Created by OncoDaily in collaboration with The Learning Lab, a digital education spin-out of Guy’s and St Thomas’ NHS Foundation Trust, and working with Guy’s Cancer Academy, the platform is designed to help healthcare professionals navigate an increasingly complex and rapidly changing cancer landscape.

The first educational initiative is a six-part programme on immune checkpoint inhibitors (ICIs), taking learners from the foundations of immuno-oncology through resistance, next-generation approaches, immune-related toxicities and their application in clinical practice.

The programme is free to access online.

Register for FREE and create your account now!

Oncology Education for a Rapidly Changing Field

Cancer care is evolving at a pace that makes continuous learning increasingly important.

New biomarkers, immunotherapies, targeted treatments and therapeutic combinations are continuously reshaping clinical practice. For clinicians, keeping up is no longer only about knowing which new drug has been approved or which trial has reported positive results.

It also means understanding the biology behind new approaches, interpreting emerging evidence critically and knowing how that evidence may influence decisions in everyday practice.

OncoDaily Academy has been developed around that need.

The platform aims to make specialist oncology education available to clinicians wherever they practise, including healthcare professionals who may have fewer opportunities to access expert-led training.

Rather than focusing only on information delivery, the educational experience is designed around clinical application, with complex concepts broken into manageable steps and connected to real-world questions, cases and patient perspectives.

The first programme: Immune checkpoint inhibitors

The inaugural OncoDaily Academy programme focuses on one of the most important developments in modern cancer treatment: immune checkpoint inhibition.

ICIs have transformed outcomes for some patients and introduced the possibility of durable disease control across several malignancies.

Yet their benefits remain far from universal.

Some tumours remain immunologically “cold.” Others demonstrate primary resistance or eventually escape immune control. At the same time, expanding immune activity can introduce distinctive toxicities that require clinicians to recognise and manage treatment-related problems differently from conventional chemotherapy.

The six-part programme is designed to build progressively through these questions.

The opening modules examine the progress and limitations of current checkpoint inhibition, the biology of cold and resistant tumours, and how next-generation ICIs are being designed to extend the reach of immunotherapy.

The programme then moves into the clinical recognition of immune-related adverse events and the practical considerations that accompany increasingly complex immunotherapy strategies.

Throughout the course, learners are encouraged not simply to memorise mechanisms, but to understand why a particular approach is being developed, what biological problem it is intended to address, and how emerging clinical evidence should be interpreted.

OncoDaily Academy Is Now Live: Free Global Oncology Education Starts Today

Learning Designed for Clinical Practice

The programme has been developed with clinicians and is structured around the questions healthcare professionals encounter in practice.

Interactive activities, clinical scenarios and case-based learning allow participants to apply concepts as they progress through the modules. The programme is intended for professionals across the cancer workforce, including oncologists, oncology trainees and nurses, as well as other healthcare professionals involved in cancer care.

Participants receive a free certificate of completion from Guy’s Cancer Academy after each individual module. Learners who complete the entire six-part programme will also receive an additional certificate recognising completion of the full course.

A global collaboration in oncology education

OncoDaily Academy is developed by OncoDaily in collaboration with The Learning Lab, a digital education team and spin-out of Guy’s and St Thomas’ NHS Foundation Trust, working with Guy’s Cancer Academy.

The Learning Lab develops clinically grounded digital education and new approaches to how healthcare professionals learn, with an emphasis on translating knowledge into practice.

By combining this educational expertise with OncoDaily’s global oncology community, OncoDaily Academy aims to broaden access to specialist cancer education and create learning experiences relevant to clinicians across different healthcare systems and career stages.

The inaugural immuno-oncology programme is delivered as independent medical education. Agenus has provided non-promotional funding and support, while editorial control of all educational content remains with the clinical and educational team.

This approach is designed to support broad access to oncology education while maintaining the independence of the educational programme.

Start Learning Today

With the launch of OncoDaily Academy, clinicians can now begin the first programme and follow the six-part learning journey through immune checkpoint inhibition.

The goal is simple: to make high-quality oncology education easier to access, easier to apply, and available to clinicians wherever they practise.

Registration is free: Create your OncoDaily Academy account now!

Nare Hovhannisyan
Fact checked by Nare Hovhannisyan MD, Medical Writer
Elen Baloyan
Medically reviewed by Elen Baloyan MD, Medical Oncologist, Vice President of News and Content strategy, OncoDaily, P53, Director of BIGR, Editor-in-Chief of OncoDaily Magazine